Clinical trial

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Osimertinib Normalized identity: osimertinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-05-30

PhasePHASE2

Conditions

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancerunresolved

Interventions

OsimertinibDRUG · verified · RxNorm: osimertinib

Sponsors & collaborators

AstraZenecalead sponsor

Parexelcollaborator

Mapped research locations

SeoulSouth Korea4 BostonMassachusetts, United States1 AtlantaGeorgia, United States1 MadridSpain1 BarcelonaSpain1 SevilleSpain1 RomaItaly1 A CoruñaSpain1 BusanSouth Korea1 BresciaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03239340 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.